

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1615HXS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	40	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS	41	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC

NEWS 42 Feb 13 CANCERLIT is no longer being updated  
 NEWS 43 Feb 24 METADEX enhancements  
 NEWS 44 Feb 24 PCTGEN now available on STN  
 NEWS 45 Feb 24 TEMA now available on STN  
 NEWS 46 Feb 26 NTIS now allows simultaneous left and right truncation  
 NEWS 47 Feb 26 PCTFULL now contains images  
 NEWS 48 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
 NEWS 49 Mar 19 APOLLIT offering free connect time in April 2003  
 NEWS 50 Mar 20 EVENTLINE will be removed from STN  
 NEWS 51 Mar 24 PATDPAFULL now available on STN  
 NEWS 52 Mar 24 Additional information for trade-named substances without structures available in REGISTRY  
 NEWS 53 Mar 24 Indexing from 1957 to 1966 added to records in CA/CAPLUS

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS INTER General Internet Information  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:52:58 ON 07 APR 2003

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 08:53:11 ON 07 APR 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Apr 2003 VOL 138 ISS 15  
 FILE LAST UPDATED: 6 Apr 2003 (20030406/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s tiotropium

L1 93 TIOTROPIUM

=> s l1 and antihistamine

5139 ANTIHISTAMINE

L2 2 L1 AND ANTIHISTAMINE

=> d 1 l1 all

L1 ANSWER 1 OF 93 CAPLUS COPYRIGHT 2003 ACS

AN 2003:242164 CAPLUS

TI Novel medicaments for inhalation

IN Linz, Guenter; Soyka, Rainer

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM A61K031-46

ICS A61K031-137; A61P011-06; A61P011-08

CC 63 (Pharmaceuticals)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024452	A1	20030327	WO 2002-EP9974	20020906
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10145438	A1	20030403	DE 2001-10145438	20010914
PRAI	DE 2001-10145438	A	20010914		
	DE 2002-10209243	A	20020304		
AB	The invention relates to novel medicament compositions based on <b>tiotropium</b> salts and poorly soluble salmeterol salts. The invention also relates to a method for the production of said compositions and to the use thereof for treating diseases of the respiratory tract.				

=> d 2 l2 all

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 1999:449797 CAPLUS

DN 131:237677

TI Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle

AU Cardelu, Ignasi; Anto, Francisca; Beleta, Jorge; Palacios, Jose M.

CS Research Center, Pharmacology Department, Almirall Prodesfarma, Barcelona, 08024, Spain

SO European Journal of Pharmacology (1999), 374(2), 249-254

CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier Science B.V.

DT Journal

LA English

CC 1-7 (Pharmacology)

AB Allergic conjunctivitis is the most common ocular allergic disease. Although very symptomatic, it does not endanger vision and topical antihistamines or hormones are the first choice of treatment in clin. practice. Recently, equiv. nanomolar affinities for histamine H1 and muscarinic M1 and M3 cloned human receptors have been reported for desloratadine, the active metabolite of loratadine, a widely prescribed **antihistamine**. This property might enhance its utility in the treatment of asthma, but could induce adverse anticholinergic effects after topical administration. In the present study, we compare the anticholinergic activity of desloratadine with other known muscarinic antagonists and antihistamines on rabbit and guinea-pig iris smooth muscle. Desloratadine was found to be a competitive antagonist ( $pA_2=6.67 \pm .0.09$ ) of carbachol-induced contractions in isolated rabbit iris smooth muscle. Atropine ( $pA_2=9.44 \pm .0.02$ ) and NPC-14695 ( $pA_2=9.18 \pm .0.03$ ) also behaved as competitive antagonists, whereas **tiotropium** bromide ( $pD_2'=9.06 \pm .0.02$ ) exhibited a non-competitive behavior in this tissue. Carebastine ( $pA_2=5.64 \pm .0.04$ ) and fexofenadine ( $pA_2 < 4.0$ ) were also studied. After topical administration on the guinea-pig eye conjunctiva, desloratadine produced a potent ( $ED_{50}=2.3$  mg/mL) and long lasting mydriasis ( $>120$  min at the  $ED_{50}$ ) in conscious animals. Fexofenadine and carebastine were inactive even at the highest concn. tested (10 mg/mL). Atropine ( $ED_{50}=30$  .mu.g/mL) and **tiotropium** bromide ( $ED_{50}=10$  .mu.g/mL) were much more potent than desloratadine or pirenzepine ( $ED_{50}=3$  mg/mL) in this model. The competitive muscarinic antagonism of desloratadine in vitro, and its potency and duration of action in vivo, suggest that topical treatment of allergic conjunctivitis and rhinitis with desloratadine could produce undesirable peripheral anticholinergic side effects such as mydriasis and xerostomia.

ST desloratadine anticholinergic iris mydriasis conjunctivitis rhinitis

IT Eye, disease  
(allergic conjunctivitis; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Allergy inhibitors  
Antihistamines  
Cholinergic antagonists  
Muscarinic antagonists  
(anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Eye  
(iris dilator muscle; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Eye, disease  
(mydriasis; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Mouth  
(xerostomia; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT 100643-71-8, Desloratadine  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Arunlakshana, A; Br J Pharmacol 1959, V14, P48
- (2) Bognar, I; Eur J Pharmacol 1989, V163, P263 CAPLUS
- (3) Bognar, I; Naunyn-Schmiedeberg's Arch Pharmacol 1990, V341, P22 CAPLUS
- (4) Bognar, I; Naunyn-Schmiedeberg's Arch Pharmacol 1992, V345, P611 CAPLUS
- (5) Cardelus, I; Br J Pharmacol 1998, V123, P267P
- (6) Choppin, A; Br J Pharmacol 1998, V124, P883 CAPLUS
- (7) Clissold, S; Drugs 1989, V37, P42 CAPLUS
- (8) Davies, R; Clin Exp Allergy 1996, V26, P11

(9) Disse, B; Life Sciences 1993, V52, P537 CAPLUS  
 (10) Disse, B; Life Sciences 1999, V64, P457 CAPLUS  
 (11) Eglen, R; Pharmacol Rev 1996, V48, P531 CAPLUS  
 (12) Fuder, H; J Ocul Pharmacol 1994, V10, P109 CAPLUS  
 (13) Genovese, A; Clin Exp Allergy 1997, V27, P559 CAPLUS  
 (14) Gil, D; Invest Ophthalmol Visual Sci 1997, V38, P1434 MEDLINE  
 (15) Handley, D; Ann Allergy Asthma Immunol 1997, V78, PP164  
 (16) Handley, D; Expert Opinion on Investigational Drugs 1998, V7, P1045 CAPLUS  
 (17) Haria, M; Drugs 1994, V48, P617 MEDLINE  
 (18) Hingorani, M; Expert Opinion on Investigational Drugs 1998, V7, P27 CAPLUS  
 (19) Howell, R; J Pharmacol Exp Ther 1994, V270, P546 CAPLUS  
 (20) Ishizaka, N; Brain Res 1998, V787, P344 CAPLUS  
 (21) Kaiser, C; J Med Chem 1993, V36, P610 CAPLUS  
 (22) Maesen, F; Eur Respir J 1995, V8, P1506 CAPLUS  
 (23) Norohna-Blob, L; J Pharmacol Exp Ther 1991, V5, P562  
 (24) Tallarida, R; The Dose-Response Relation in Pharmacology 1979  
 (25) Vignola, A; Allergy 1995, V50, P200 CAPLUS  
 (26) Weyer, A; J Allergy Clin Immunol 1992, V89, P222  
 (27) Woldemussie, E; Exp Eye Res 1993, V56, P385 CAPLUS  
 (28) Yoshitomi, T; Graefe's Arch Clin Exp Ophthalmol 1995, V233, P181 CAPLUS  
 (29) Yumibe, N; Biochem Pharmacol 1996, V51, P165 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 08:52:58 ON 07 APR 2003)

FILE 'CAPLUS' ENTERED AT 08:53:11 ON 07 APR 2003

L1 93 S TIOTROPIUM  
 L2 2 S L1 AND ANTIHISTAMINE

=> s l1 and epinastine or cetirizine

146 EPINASTINE  
 622 CETIRIZINE  
 L3 624 L1 AND EPINASTINE OR CETIRIZINE

=> s l1 and l3

L4 7 L1 AND L3

=> d 1 l1 all

L1 ANSWER 1 OF 93 CAPLUS COPYRIGHT 2003 ACS  
 AN 2003:242164 CAPLUS  
 TI Novel medicaments for inhalation  
 IN Linz, Guenter; Soyka, Rainer  
 PA Boehringer Ingelheim Pharma K.-G., Germany  
 SO PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 IC ICM A61K031-46  
 ICS A61K031-137; A61P011-06; A61P011-08  
 CC 63 (Pharmaceuticals)  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024452	A1	20030327	WO 2002-EP9974	20020906
	W:				
					AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
					CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
					GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,  
 RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG

DE 10145438 A1 20030403 DE 2001-10145438 20010914  
 PRAI DE 2001-10145438 A 20010914  
 DE 2002-10209243 A 20020304

AB The invention relates to novel medicament compositions based on  
**tiotropium** salts and poorly soluble salmeterol salts. The  
 invention also relates to a method for the production of said  
 compositions  
 and to the use thereof for treating diseases of the respiratory tract.

=> d 2 12 all

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 1999:449797 CAPLUS

DN 131:237677

TI Anticholinergic effects of desloratadine, the major metabolite of  
 loratadine, in rabbit and guinea-pig iris smooth muscle

AU Cardelu, Ignasi; Anto, Francisca; Beleta, Jorge; Palacios, Jose M.

CS Research Center, Pharmacology Department, Almirall Prodesfarma,  
 Barcelona,  
 08024, Spain

SO European Journal of Pharmacology (1999), 374(2), 249-254

CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier Science B.V.

DT Journal

LA English

CC 1-7 (Pharmacology)

AB Allergic conjunctivitis is the most common ocular allergic disease.  
 Although very symptomatic, it does not endanger vision and topical  
 antihistamines or hormones are the first choice of treatment in clin.  
 practice. Recently, equiv. nanomolar affinities for histamine H1 and  
 muscarinic M1 and M3 cloned human receptors have been reported for  
 desloratadine, the active metabolite of loratadine, a widely prescribed  
**antihistamine**. This property might enhance its utility in the  
 treatment of asthma, but could induce adverse anticholinergic effects  
 after topical administration. In the present study, we compare the  
 anticholinergic activity of desloratadine with other known muscarinic  
 antagonists and antihistamines on rabbit and guinea-pig iris smooth  
 muscle. Desloratadine was found to be a competitive antagonist  
 ( $pA_2=6.67 \pm 0.09$ ) of carbachol-induced contractions in isolated rabbit  
 iris smooth muscle. Atropine ( $pA_2=9.44 \pm 0.02$ ) and NPC-14695  
 ( $pA_2=9.18 \pm 0.03$ ) also behaved as competitive antagonists, whereas  
**tiotropium** bromide ( $pD_2'=9.06 \pm 0.02$ ) exhibited a non-competitive  
 behavior in this tissue. Carebastine ( $pA_2=5.64 \pm 0.04$ ) and fexofenadine  
 ( $pA_2<4.0$ ) were also studied. After topical administration on the  
 guinea-pig eye conjunctiva, desloratadine produced a potent ( $ED_{50}=2.3$   
 mg/mL) and long lasting mydriasis (>120 min at the  $ED_{50}$ ) in conscious  
 animals. Fexofenadine and carebastine were inactive even at the highest  
 concn. tested (10 mg/mL). Atropine ( $ED_{50}=30 \mu\text{g/mL}$ ) and  
**tiotropium** bromide ( $ED_{50}=10 \mu\text{g/mL}$ ) were much more potent than  
 desloratadine or pirenzepine ( $ED_{50}=3 \text{ mg/mL}$ ) in this model. The  
 competitive muscarinic antagonism of desloratadine in vitro, and its  
 potency and duration of action in vivo, suggest that topical treatment of  
 allergic conjunctivitis and rhinitis with desloratadine could produce  
 undesirable peripheral anticholinergic side effects such as mydriasis and  
 xerostomia.

ST desloratadine anticholinergic iris mydriasis conjunctivitis rhinitis

IT Eye, disease  
 (allergic conjunctivitis; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Allergy inhibitors  
 Antihistamines  
 Cholinergic antagonists  
 Muscarinic antagonists  
 (anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Eye  
 (iris dilator muscle; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Eye, disease  
 (mydriasis; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Mouth  
 (xerostomia; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT 100643-71-8, Desloratadine  
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Arunlakshana, A; Br J Pharmacol 1959, V14, P48
- (2) Bognar, I; Eur J Pharmacol 1989, V163, P263 CAPLUS
- (3) Bognar, I; Naunyn-Schmiedeberg's Arch Pharmacol 1990, V341, P22 CAPLUS
- (4) Bognar, I; Naunyn-Schmiedeberg's Arch Pharmacol 1992, V345, P611 CAPLUS
- (5) Cardelus, I; Br J Pharmacol 1998, V123, P267P
- (6) Choppin, A; Br J Pharmacol 1998, V124, P883 CAPLUS
- (7) Clissold, S; Drugs 1989, V37, P42 CAPLUS
- (8) Davies, R; Clin Exp Allergy 1996, V26, P11
- (9) Disse, B; Life Sciences 1993, V52, P537 CAPLUS
- (10) Disse, B; Life Sciences 1999, V64, P457 CAPLUS
- (11) Eglen, R; Pharmacol Rev 1996, V48, P531 CAPLUS
- (12) Fuder, H; J Ocul Pharmacol 1994, V10, P109 CAPLUS
- (13) Genovese, A; Clin Exp Allergy 1997, V27, P559 CAPLUS
- (14) Gil, D; Invest Ophthalmol Visual Sci 1997, V38, P1434 MEDLINE
- (15) Handley, D; Ann Allergy Asthma Immunol 1997, V78, PP164
- (16) Handley, D; Expert Opinion on Investigational Drugs 1998, V7, P1045 CAPLUS
- (17) Haria, M; Drugs 1994, V48, P617 MEDLINE
- (18) Hingorani, M; Expert Opinion on Investigational Drugs 1998, V7, P27 CAPLUS
- (19) Howell, R; J Pharmacol Exp Ther 1994, V270, P546 CAPLUS
- (20) Ishizaka, N; Brain Res 1998, V787, P344 CAPLUS
- (21) Kaiser, C; J Med Chem 1993, V36, P610 CAPLUS
- (22) Maesen, F; Eur Respir J 1995, V8, P1506 CAPLUS
- (23) Norohna-Blob, L; J Pharmacol Exp Ther 1991, V5, P562
- (24) Tallarida, R; The Dose-Response Relation in Pharmacology 1979
- (25) Vignola, A; Allergy 1995, V50, P200 CAPLUS
- (26) Weyer, A; J Allergy Clin Immunol 1992, V89, P222
- (27) Woldemussie, E; Exp Eye Res 1993, V56, P385 CAPLUS
- (28) Yoshitomi, T; Graefe's Arch Clin Exp Ophthalmol 1995, V233, P181 CAPLUS
- (29) Yumibe, N; Biochem Pharmacol 1996, V51, P165 CAPLUS

=> d 3 13 all

L3 ANSWER 3 OF 624 CAPLUS COPYRIGHT 2003 ACS  
 AN 2003:203393 CAPLUS

DN 138:226774  
 TI Preparation of liquid and semisolid dosage forms containing drug tannate salts  
 IN Kiel, Jeffrey S.; Thomas, H. Greg; Mani, Narasimhan  
 PA USA  
 SO U.S. Pat. Appl. Publ., 8 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-7024  
 ICS C07H013-02  
 NCL 514023000; 536110000  
 CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003050252	A1	20030313	US 2002-119285	20020409
PRAI	US 2001-282969P	P	20010410		

AB An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purifn. is then added to a liq. or

semi-solid

medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liq. or semi-solid medium to generate a therapeutic dosage form. A suspension with xanthan gum as thickening agent was prepd. from a formulation contg. pseudoephedrine tannate 1.500, diphenhydramine tannate 0.500, saccharin sodium 0.300, sucrose 10.000, glycerin 7.500, Mg Al silicate 0.800, xanthan gum 0.520, dibasic sodium phosphate 1.000, methylparaben 0.200, sodium benzoate 0.100, FD&C Red No.-40 0.040, strawberry flavor 0.500,

and

water qs to 100%.

ST drug tannate salt liq dosage form; semisolid dosage form drug tannate

salt

IT Drug delivery systems

(liqs.; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Antihistamines

Antitussives

Cholinergic antagonists

Decongestants

Flavoring materials

Preservatives

Sweetening agents

Thickening agents

(prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Paraffin oils

Tannins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Drug delivery systems

(semisolid; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Drug delivery systems

(suspensions; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Kaolin, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(thickener; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT 56-81-5, Glycerin, biological studies 57-27-2, Morphine, biological

studies 57-55-6, Propylene glycol, biological studies 58-73-1,

Diphenhydramine 58-73-1D, Diphenhydramine, tannic acid salts 59-33-6,



Pyrillamine maleate 59-42-7, Phenylephrine 59-42-7D, Phenylephrine, tannic acid salts 60-87-7, Promethazine 61-76-7, Phenylephrine hydrochloride 64-17-5, Ethanol, biological studies 67-63-0, Isopropyl alcohol, biological studies 68-88-2, Hydroxyzine 76-42-6, Oxycodone 76-57-3, Codeine 77-23-6, Carbetapentane 82-88-2, Phenindamine 82-93-9, Chlorcyclizine 84-96-8, Trimeprazine 86-21-5, Pheniramine 86-22-6, Brompheniramine 90-82-4, Pseudoephedrine 90-82-4D, Pseudoephedrine, tannic acid salts 91-81-6, Tripeleminamine 91-84-9, Pyrillamine 91-84-9D, Pyrillamine, tannic acid salts 92-12-6, Phenyltoloxamine 118-23-0, Bromodiphenhydramine 125-29-1, Hydrocodone 125-69-9, Dextromethorphan hydrobromide 125-71-3, Dextromethorphan 129-03-3, Cyproheptadine 132-22-9, Chlorpheniramine 132-22-9D, Chlorpheniramine, tannic acid salts 299-42-3, Ephedrine 345-78-8, Pseudoephedrine hydrochloride 469-21-6, Doxylamine 486-12-4, Triprolidine 486-16-8, Carbinoxamine 523-87-5, Dimenhydrinate 569-65-3, Meclizine 13265-10-6, Methscopolamine 15686-51-8, Clemastine 23142-01-0, Carbetapentane citrate 79794-75-5, Loratadine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 87848-99-5, Acrivastine 100643-71-8, Desloratadine  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (prepn. of liq. and semisolid dosage forms contg. drug tannate salts)  
 IT 1327-43-1, Magnesium aluminum silicate 9000-69-5, Pectin 9004-34-6, Cellulose, biological studies 9004-65-3, HPMC 11138-66-2, Xanthan gum  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (thickener; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

=> d 4 14 all

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:353315 CAPLUS  
 DN 136:374833  
 TI Inhalant composition containing **tiotropium** salts and anti-histamines  
 IN Pairet, Michel; Pieper, Michael Paul; Meade, Christopher John Montague; Schmelzer, Christel  
 PA Boehringer Ingelheim Pharma Kg, Germany  
 SO PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 IC ICM A61K045-00  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1  
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002036163	A2	20020510	WO 2001-EP12510	20011023
	WO 2002036163	A3	20021212		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	DE 10138272	A1	20030227	DE 2001-10138272	20010810
	US 2002151541	A1	20021017	US 2001-7182	20011019
	US 2002183292	A1	20021205	US 2001-86145	20011019
	AU 2002014030	A5	20020515	AU 2002-14030	20011023
	US 2002137764	A1	20020926	US 2001-40196	20011025

PRAI DE 2000-10054042 A 20001031  
 DE 2001-10138272 A 20010810  
 US 2000-253613P P 20001128  
 DE 2000-10062712 A 20001215  
 US 2000-257220P P 20001221  
 US 2001-314599P P 20010824  
 WO 2001-EP12510 W 20011023

AB The invention relates to inhalant compns. based on **tiotropium** salts and anti-histamines, a method for their prodn. and their use for treating respiratory illnesses, e.g. allergic and non-allergic rhinitis. Thus and inhalation powder contained per microcapsule (.mu.g): **tiotropium** bromide 21.7; **epinastine**-hydrochloride 200; lactose 4778.3.

ST **tiotropium** antihistamine inhalant nose allergy

IT Quaternary ammonium compounds, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alkylbenzylidimethyl, chlorides; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Respiratory tract  
 (allergy; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Respiratory tract  
 (disease; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Glycols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (ethers; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Ethers, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (glycol; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Hydrocarbons, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (halo; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Antihistamines  
 Antioxidants  
 Complexing agents  
 Lubricants  
 Particle size  
 Propellants (sprays and foams)  
 Stabilizing agents  
 Surfactants  
 pH  
 (inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Monosaccharides  
 Oligosaccharides, biological studies  
 Polyoxyalkylenes, biological studies  
 Polysaccharides, biological studies  
 Tocopherols  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Drug delivery systems  
 (inhalants; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Medical goods  
 (inhalers; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Drug delivery systems  
 (microcapsules; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polyhydric; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Drug delivery systems  
(suspensions; inhalant compn. contg. **tiotropium** salts and  
anti-histamines)

IT 50-81-7, L-Ascorbic acid, biological studies 56-81-5, Glycerol,  
biological studies 57-55-6, Propylene glycol, biological studies  
58-73-1, Diphenhydramine 60-00-4, EDTA, biological studies 60-87-7,  
Promethazine 64-17-5, Ethanol, biological studies 64-18-6, Formic  
acid, biological studies 64-19-7, Acetic acid, biological studies  
65-85-0, Benzoic acid, biological studies 65-85-0D, Benzoic acid, salts  
74-82-8D, Methane, halogenated derivs. 74-84-0D, Ethane, halogenated  
derivs. 74-98-6, Propane, biological studies 74-98-6D, Propane,  
halogenated derivs. 75-19-4D, Cyclopropane, halogenated derivs.  
75-28-5, Isobutane 77-38-3, Chlorphenoxamine 77-92-9, Citric acid,  
biological studies 79-09-4, Propionic acid, biological studies  
86-21-5, Pheniramine 106-97-8, Butane, biological studies 106-97-8D,  
Butane, halogenated derivs. 110-15-6, Succinic acid, biological studies  
110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid,  
biological studies 123-03-5, Cetylpyridinium chloride 139-33-3  
287-23-0D, Cyclobutane, halogenated derivs. 431-89-0, TG 227  
469-21-6,  
Doxylamine 523-87-5, Dimenhydrinate 526-83-0, Tartaric acid  
569-65-3, Meclozine 811-97-2, TG 134a 1406-18-4, Vitamin E  
4945-47-5, Bamipine 5636-83-9, Dimetindene 6915-15-7, Malic acid  
7647-01-0, Hydrochloric acid, biological studies 7664-93-9, Sulfuric  
acid, biological studies 7697-37-2, Nitric acid, biological studies  
10035-10-6, Hydrobromic acid, biological studies 11103-57-4, Vitamin A  
15686-51-8, Clemastine 25322-68-3, Polyethylene glycol 25322-69-4,  
Polypropylene glycol 34580-13-7, Ketotifen 58581-89-8, Azelastine  
79516-68-0, Levocabastine 79794-75-5, Loratadine 80012-43-7,  
**Epinaestine** 83799-24-0, Fexofenadine 83881-51-0,  
**Cetirizine** 87233-61-2, Emedastine 90729-43-4, Ebastine  
100643-71-8, Desloratadine 108612-45-9, Mizolastine 108929-04-0,  
**Epinaestine** hydrochloride 136310-93-5, **Tiotropium**  
bromide 186691-13-4D, **Tiotropium**, salts 412010-60-7  
412010-61-8 412010-62-9 412010-63-0 412010-64-1  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(inhalant compn. contg. **tiotropium** salts and anti-histamines)

=> d 5 15 all

L5 NOT FOUND

The L-number entered has not been defined in this session, or it  
has been deleted. To see the L-numbers currently defined in this  
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=>

=> d his

(FILE 'HOME' ENTERED AT 08:52:58 ON 07 APR 2003)

FILE 'CAPLUS' ENTERED AT 08:53:11 ON 07 APR 2003

L1 93 S TIOTROPIUM  
L2 2 S L1 AND ANTIHISTAMINE  
L3 624 S L1 AND EPINASTINE OR CETIRIZINE  
L4 7 S L1 AND L3

=> d 5 15 all

L5 NOT FOUND

The L-number entered has not been defined in this session, or it  
has been deleted. To see the L-numbers currently defined in this  
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d 6 16 all

L6 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s tiotropium

L5 93 TIOTROPIUM

=> s 15 and (epinastine or cetirizine)

146 EPINASTINE

622 CETIRIZINE

L6 7 L5 AND (EPINASTINE OR CETIRIZINE)

=> d 5 15 all

L5 ANSWER 5 OF 93 CAPLUS COPYRIGHT 2003 ACS

AN 2003:133126 CAPLUS

DN 138:175957

TI Inhalation device with a pharmaceutical composition containing an .beta.-adrenoceptor agonist and an anticholinergic agent

IN Richards, David Hugh

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61M015-00

ICS A61K009-00; A61K031-46; A61K031-135

CC 63-8 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003013633	A1	20030220	WO 2002-EP8718	20020805
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI GB 2001-19408 A 20010809

GB 2001-19411 A 20010809

AB An inhalation device comprising plural doses of medicament in powder form is provided, wherein the medicament is a pharmaceutical formulation comprising (i) salmeterol or a pharmaceutically acceptable salt, solvate, or physiol. functional deriv. thereof, (ii) an anticholinergic agent or a pharmaceutically acceptable salt, solvate, or physiol. functional deriv. thereof, (iii) a pharmaceutically acceptable carrier or excipient, and (iv) optionally one or more other therapeutic ingredients. The device

and

the powder compn. are used for the prophylaxis and treatment of a disease assocd. with reversible airways obstruction, such as asthma, COPD, respiratory tract infection, or upper respiratory tract disease.

ST salmeterol anticholinergic inhalation powder device

IT Drug delivery systems

(blister packs; inhalation device with powder compn. contg. salmeterol

and anticholinergic agent)

IT Butyl rubber, biological studies  
 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (chlorinated; inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT Lung, disease  
 (chronic obstructive; inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT Respiratory tract  
 (disease, obstructive, reversible; inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT Respiratory tract  
 (infection; inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT Asthma  
 Cholinergic antagonists  
 (inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT Butyl rubber, biological studies  
 Laminated plastics, biological studies  
 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT Medical goods  
 (inhalers; inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT Drug delivery systems  
 (powders, inhalants; inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT Fluoropolymers, biological studies  
 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (rubber laminated with; inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT Respiratory tract  
 (upper, disease; inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT Adrenoceptor agonists  
 (.beta.-; inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT 9010-85-9  
 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (butyl rubber, chlorinated; inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT 9010-85-9  
 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (butyl rubber, inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT 55-48-1, Atropine sulfate 22254-24-6, Ipratropium bromide 30286-75-0, Oxitropium bromide 89365-50-4, Salmeterol 94749-08-3, Salmeterol xinafoate 136310-93-5, Tiotropium bromide 149926-91-0, Revatropate  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhalation device with powder compn. contg. salmeterol and anticholinergic agent)

IT 9002-84-0, PTFE 9002-88-4, Polyethylene 9003-07-0, Polypropylene  
 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (rubber laminated with; inhalation device with powder compn. contg.

salmeterol and anticholinergic agent)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Birsha, D; US 6032666 A 2000
- (2) Dmitrovic, B; WO 9830262 A 1998
- (3) Glaxo Group Ltd; GB 2169265 A 1986
- (4) Glaxo Wellcome Inc; EP 0987041 A 2000
- (5) Noord van, J; EUROPEAN RESPIRATORY JOURNAL 2000, V15(5), P878
- (6) Peter, M; WO 9948475 A 1999 CAPLUS
- (7) Skyepharma Ag; WO 0028979 A 2000 CAPLUS
- (8) Walland, A; WO 0069468 A 2000
- (9) Walland, A; WO 02060532 A 2002 CAPLUS

=> d 6 16 all

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2001:137173 CAPLUS

DN 134:178396

TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction

IN Del Soldato, Piero

PA Nicox S.A., Fr.

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07C219-14

ICS C07C219-30; C07C229-42; C07C233-25; C07D219-10; C07D295-08;

C07D309-30; C07D401-12; C07D471-04; C07D495-04; C07D499-68;

C07H015-252; A61K031-21; C07D495-00; C07D333-00; C07D213-00

CC 26-1 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
	WO 2001012584	A3	20020829		
	W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 2000013264	A	20020416	BR 2000-13264	20000727
	EP 1252133	A2	20021030	EP 2000-953102	20000727
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	NO 2002000623	A	20020409	NO 2002-623	20020208
PRAI	IT 1999-MI1817	A	19990812		
	WO 2000-EP7225	W	20000727		

OS MARPAT 134:178396

AB Compds. or their salts of general formula (I): A-B-N(O)<sub>s</sub> wherein: s is an integer equal to 1 or 2; A = R-T1-, wherein R is the drug radical and T1

=

(CO)<sub>t</sub> or (X)<sub>t'</sub>, wherein X = O, S, NR1c, R1c is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t = 1 when t' = 0; t = 0 when t' = 1; B = -TB

-X2-O-

wherein TB = (CO) when t = 0, TB = X when t' = 0, X being as above defined; X2, bivalent radical, is such that the precursor drug of A and the precursor of B meet resp. the pharmacol. tests described in the description. Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction

are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.

ST pharmaceutical compd prepn oxidative stress treatment; endothelial dysfunction treatment pharmaceutical compd prepn; precursor antiinflammatory analgesic bronchodilator expectorant; antiasthmatic antihistaminic ACE inhibitor beta blocker precursor; antithrombotic vasodilator antidiabetic antitumor antiulcer precursor; antihyperlipidemic antibiotic antiviral antidementia precursor; bone resorption inhibitor precursor

IT Mental disorder  
(dementia; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

IT Bone  
(resorption, inhibitors; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

IT Analgesics  
Anti-inflammatory agents  
Antiasthmatics  
Antibiotics  
Anticoagulants  
Antidiabetic agents  
Antihistamines  
Antitumor agents  
Antiulcer agents  
Antiviral agents  
Bronchodilators  
Cytotoxicity  
Expectorants  
Hypolipemic agents  
Vasodilators  
(synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

IT Adrenoceptor antagonists  
(.beta.-; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

IT 34661-75-1, Urapidil 62571-86-2, Captopril 74258-86-9, Alacepril 76420-72-9, Enalaprilat 76547-98-3, Lisinopril 82834-16-0, Perindopril 83435-66-9, Delapril 83647-97-6, Spirapril 85441-61-8, Quinapril 85856-54-8, Moveltipril 86541-75-5, Benazepril 87333-19-5, Ramipril 87679-37-6, Trandolapril 88768-40-5, Cilazapril 89371-37-9, Imidapril 98048-97-6, Fosinopril 111223-26-8, Ceronapril 111902-57-9, Temocapril 114798-26-4, Losartan

RL: RCT (Reactant); RACT (Reactant or reagent)  
(ACE-inhibitor; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

IT 50-33-9, Phenylbutazone, reactions 57-27-2, Morphine, reactions 65-45-2 76-41-5, Oxymorphone 76-42-6, Oxycodone 76-57-3, Codeine 76-58-4, Ethylmorphine 77-07-6, Levorphanol 94-10-0, Ethoxazene 97-53-0, Eugenol 103-97-9, Phenocoll 118-55-8, Phenyl salicylate 118-57-0, Acetaminosalol 125-29-1, Hydrocodone 127-35-5, Phenazocine 132-60-5, Cinchophen 138-52-3, Salicin 143-52-2, Metopon 144-14-9, Anileridine 326-43-2, Phenylramidol hydrochloride 359-83-1, Pentazocine 404-86-4, Capsaicine 427-00-9, Desomorphine 466-97-7, Normorphine 466-99-9, Hydromorphone 468-56-4, Hydroxypethidine 486-79-3, Dipyroceetyl 509-60-4, Dihydromorphine 530-75-6, Acetylsalicylsalicylic acid 539-08-2, p-Lactophenetide 545-90-4, Dimepheptanol 562-26-5, Phenoperidine 639-48-5, Nicomorphine 1083-57-4, Bucetin 1503-53-3 1531-12-0, Norlevorphanol 1553-60-2, Ibufenac 3567-76-8, Aminochlorthenoxazin 3734-52-9, Metazocine

3820-67-5, Glafenine 6064-83-1, Fösfosal 13739-02-1, Diacerein  
 14297-87-1, Benzyl morphine 17737-65-4, Clonixin 18699-02-0, Actarit  
 20594-83-6, Nalbuphine 23779-99-9, Floctafenine 25803-14-9,

Clometacin  
 27203-92-5, Tramadol 42408-82-2, Butorphanol 51234-28-7, Benoxaprofen  
 52485-79-7, Buprenorphine 53648-55-8, Dezocine 54340-58-8, Meptazinol  
 63269-31-8, Ciramadol 65110-93-2, Dihydroxycodine 72522-13-5,  
 Eptazocine 76721-89-6, Thiorphan

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (analgesic; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

IT 1400-61-9, Nystatin 11120-15-3, Dermostatin 26305-03-3, Pepstatin  
 73573-88-3, Mevastatin 75330-75-5, Lovastatin 81131-70-6, Pravastatin  
 sodium 82009-34-5, Cilastatin 93957-54-1, Fluvastatin 134523-00-5,  
 Atorvastatin

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (anti-hyperlipidemic; synthesis, activity and formulations of  
 pharmaceutical compds. for treatment of oxidative stress and/or  
 endothelial dysfunction)

IT 51-45-6, Histamine, reactions 68-88-2, Hydroxyzine 1159-93-9,  
 Clobenzepam 5486-77-1, Alloclamide 13946-02-6, Metron S 15826-37-6,  
 Cromoglycate 16110-51-3, Cromolyn 50679-08-8, Terfenadine  
 53237-59-5, Urushiol 53882-12-5, Lodoxamide 68302-57-8, Amlexanox  
 69049-73-6, Nedocromil 73080-51-0, Repirinast 73573-87-2, Formoterol  
 79516-68-0, Levocabastine 80012-43-7, **Epinastine** 83799-24-0,  
 Fexofenadine 87848-99-5, Acrivastine 94055-76-2, Suplatast tosylate  
 112665-43-7, Seratrodast 158966-92-8, Montelukast

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (antiasthmatic; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

IT 50-59-9, Cephaloridine 54-85-3, Isoniazid 56-75-7, Chloramphenicol  
 57-62-5 57-67-0, Sulfaguanidine 57-68-1, Sulfamethazine 57-92-1,  
 Streptomycin, reactions 60-54-8, Tetracycline 61-24-5, Cephalosporin

C  
 61-33-6, Benzyl penicillinic acid, reactions 61-72-3, Cloxacillin  
 63-74-1, Sulfanilamide 65-49-6, p-Aminosalicylic acid 66-79-5,  
 Oxacillin 68-35-9, Sulfadiazine 68-41-7, Cycloserine 72-14-0,  
 Sulfathiazole 74-55-5, Ethambutol 74-79-3, Arginine, reactions  
 79-57-2, Oxytetracycline 80-02-4, 2-p-Sulfanilylanilinoethanol  
 80-03-5, Acediasulfone 80-08-0, Dapsone 80-32-0, Sulfachlorpyridazine  
 80-35-3, Sulfamethoxypyridazine 87-08-1, Penicillin V 87-09-2,  
 Penicillin O 94-19-9, Sulfaethidole 103-12-8, Sulfamidochrysoidine  
 113-98-4, Penicillin G potassium 114-07-8, Erythromycin 115-68-4,  
 Sulfadicramide 116-42-7, Sulfaproxyline 116-44-9, Sulfapyrazine  
 119-59-5, 4,4'-Sulfinyldianiline 120-34-3, N-Sulfanilyl-3,4-xylamide  
 122-11-2, Sulfadimethoxine 127-33-3, Demeclocycline 127-69-5,  
 Sulfisoxazole 127-71-9, Sulfabenzamide 127-79-7, Sulfamerazine  
 128-46-1, Dihydrostreptomycin 130-16-5, Cloxyquin 132-92-3,  
 Methicillin sodium 132-93-4, Phenethicillin potassium 133-11-9,

Phenyl  
 aminosalicylate 138-39-6, Mafenide 144-80-9, Sulfacetamide  
 144-82-1,  
 Sulfamethizole 144-83-2, Sulfapyridine 152-47-6, Sulfalene  
 153-61-7,  
 Cephalothin 154-21-2, Lincomycin 303-81-1, Novobiocin 389-08-2  
 443-48-1, Metronidazole 473-30-3, Thiazolsulfone 485-41-6,  
 Sulfachrysoidine 495-84-1, Salinazid 515-49-1, Sulfathiourea  
 515-59-3, Sulfamethylthiazole 515-64-0, Sulfisomidine 525-94-0,  
 Penicillin N 526-08-9, Sulfaphenazole 547-44-4, Sulfanilylurea  
 547-52-4, N4-Sulfanilylsulfanilamide 547-53-5, 4'-  
 (Methylsulfamoyl)sulfanilamide 551-27-9, Propicillin 599-88-2,  
 Sulfaperine 651-06-9, Sulfameter 723-46-6, Sulfamethoxazole  
 729-99-7, Sulfamoxole 751-97-3, Rolitetracycline 808-26-4, Sancycline  
 914-00-1, Methacycline 992-21-2, Lymecycline 1110-80-1, Pipacycline



1181-54-0, Clomocycline 1403-66-3, Gentamicin 1404-04-2, Neomycin  
 1596-63-0, Quinacillin 1614-20-6, Nifurprazine 1695-77-8,  
 Spectinomycin 1926-49-4, Clometocillin 1984-94-7, Sulfasymazine  
 2013-58-3, Meclocycline 2030-63-9, Clofazimine 2315-08-4,  
 Salazosulfadimidine 2447-57-6, Sulfadoxine 2750-76-7, Rifamide  
 2751-09-9, Troleandomycin 2779-55-7, Opiniazone 3116-76-5,  
 Dicloxacillin 3485-14-1, Cyclacillin 3511-16-8, Hetacillin  
 3577-01-3, Cephaloglycin 3590-05-4, Acetyl sulfamethoxypyrazine  
 3691-74-5, Glyconiazide 3772-76-7, Sulfamethomidine 3922-90-5,  
 Oleandomycin 4008-48-4, Nitroxoline 4393-19-5, p-Sulfanilylbenzyl  
 amine 4564-87-8, Carbomycin 4697-36-3, Carbenicillin 5250-39-5,  
 Floxacillin 5934-14-5, Succisulfone 6202-21-7, 4-  
 Sulfanilamidosalicylic acid 6489-97-0, Metampicillin 6946-29-8,  
 p-Aminosalicylic acid hydrazide 6998-60-3, Rifamycin 7542-37-2,  
 Paromomycin 8025-81-8, Spiramycin 10118-90-8, Minocycline  
 11003-38-6, Capreomycin 11006-76-1, Virginiamycin 12650-69-0,  
 Mupirocin 13411-16-0, Nifurpirinol 13838-08-9, Azidamfenicol  
 13898-58-3, Benzoylpas 13925-12-7, Myxin 15599-51-6, Apicycline  
 15686-71-2, Cephalixin 16545-11-2, Guamecycline 16846-24-5, Josamycin  
 17243-38-8, Azidocillin 17784-12-2, Sulfacytine 18323-44-9,  
 Clindamycin 19562-30-2, Piromidic acid 23239-41-0, Cephacetrile  
 sodium  
 23477-98-7, Sedecamycin 24356-60-3, Cephapirin sodium 25546-65-0,  
 Ribostamycin 25953-19-9, Cefazolin 26086-49-7,  
 Deoxydihydrostreptomycin 26774-90-3, Epicillin 26787-78-0,  
 Amoxicillin  
 26973-24-0, Ceftezole 27031-08-9, Sulfaguanole 28657-80-9, Cinoxacin  
 32385-11-8, Sisomicin 32887-01-7, Amdinocillin 32909-92-5,  
 Sulfametrole 32986-56-4, Tobramycin 32988-50-4, Viomycin  
 33103-22-9,  
 Enviomycin 33404-78-3, Negamycin 33817-20-8, Pivampicillin  
 34444-01-4, Cefamandole 34493-98-6, Dibekacin 34787-01-4, Ticarcillin  
 35457-80-8, Midecamycin 35531-88-5, Carindacillin 35607-66-0,  
 Cefoxitin 35834-26-5, Rosaramicin 37091-66-0, Azlocillin  
 37321-09-8,  
 Apramycin 37517-28-5, Amikacin 38129-37-2, Bicozamycin 38821-53-3,  
 Cephadrine 41744-40-5, Sulbenicillin 42835-25-6, Flumequine  
 47747-56-8, Talampicillin 50370-12-2, Cefadroxil 50972-17-3,  
 Bacampicillin 51025-85-5, Arbekacin 51481-65-3, Mezlocillin  
 51627-14-6, Cefatrizine 51762-05-1, Cefroxadine 51940-44-4, Pipemidic  
 acid 52093-21-7, Micronomicin 52152-93-9 53994-73-3, Cefaclor  
 55268-75-2, Cefuroxime 55881-07-7, Miokamycin 56187-47-4, Cefazedone  
 56391-56-1, Netilmicin 56796-20-4, Cefmetazole 58001-44-8, Clavulanic  
 acid 60925-61-3, Ceforanide 61270-58-4, Cefonicid 61379-65-5,  
 Rifapentine 61477-96-1, Piperacillin 61622-34-2, Cefotiam  
 62013-04-1, Dirythromycin 62893-19-0, Cefoperazone 63358-49-6,  
 Aspoxicillin 63469-19-2, Apalcillin 63527-52-6, Cefotaxime  
 63836-75-9, Cephalixin pivaloxymethyl ester 64221-86-9, Imipenem  
 64952-97-2, Moxalactam 65052-63-3, Cefetamet 65085-01-0, Cefmenoxime  
 66148-78-5, Temocillin 68373-14-8, Sulbactam 68401-81-0, Ceftizoxime  
 69712-56-7, Cefotetan 69739-16-8, Cefodizime 70458-92-3, Pefloxacin  
 70458-96-7, Norfloxacin 70797-11-4, Cefpiramide 71426-83-0,  
 Fortimicin  
 72558-82-8, Ceftazidime 72559-06-9, Rifabutine 73384-59-5  
 74011-58-8, Enoxacin 74014-51-0, Rokitamycin 76470-66-1, Loracarbef  
 76497-13-7, Sultamicillin 76610-84-9, Cefbuperazone 78110-38-0,  
 Aztreonam 79350-37-1, Cefixime 79548-73-5, Pirlimycin 79660-72-3,  
 Fleroxacin 80370-57-6, Ceftiofur 80621-81-4, Rifaximin 81103-11-9,  
 Clarithromycin 82219-78-1, Cefuzonam 82419-36-1, Ofloxacin  
 82547-58-8, Cefteram 83905-01-5, Azithromycin 84305-41-9, Cefminox  
 84845-57-8, Ritipenem 84880-03-5, Cefpimizole 84957-29-9, Cefpirome  
 85721-33-1, Ciprofloxacin 86273-18-9, Lenampicillin 87239-81-4,  
 Cefpodoxime proxetil 87638-04-8, Carumonam 87726-17-8, Panipenem  
 88040-23-7, Cefepime 88669-04-9, Trospespectomycin 91832-40-5, Cefdinir  
 92665-29-7, Cefprozil 93106-60-6, Enrofloxacin 96036-03-2, Meropenem  
 97519-39-6, Ceftibuten 98079-51-7 98106-17-3, Difloxacin

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (antibiotic; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

IT 99665-00-6, Flomoxef 100490-36-6, Tosufloxacin 101363-10-4,  
 Rufloxacin  
 102507-71-1, Tigemonam 104145-95-1, Cefditoren 105239-91-6,  
 Cefclidin 105889-45-0, Cefcapene pivoxil 105956-97-6, Clinafloxacin  
 110871-86-8, Sparfloxacin 113359-04-9, Cefozopran 119914-60-2,  
 Grepafloxacin 120410-24-4, Biapenem 124858-35-1, Nadifloxacin  
 127045-41-4, Pazufloxacin 147059-72-1, Trovafloxacin

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (antibiotic; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

IT 62613-82-5, Oxiracetam 62732-44-9, Ipidacrine 90043-86-0, Amiridine  
 97205-34-0, Nebracetam 103878-84-8, Lazabemide 119386-96-8,  
 Mofegiline  
 124027-47-0, Velnacrine

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (antidementia; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

IT 339-43-5, Carbutamide 4618-41-1, 1-Butyl-3-metanilylurea 26944-48-9,  
 Glibornuride 56180-94-0, Acarbose 72432-03-2, Miglitol 97322-87-7,  
 Troglitazone 135062-02-1, Repaglinide

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (antidiabetic; synthesis, activity and formulations of pharmaceutical  
 compds. for treatment of oxidative stress and/or endothelial  
 dysfunction)

IT 53-86-1, Indomethacin 61-68-7, Mefenamic acid 87-28-5, Glylcol  
 salicylate 89-45-2, Salicylsulfuric acid 89-57-6, Mesalamine  
 129-20-4, Oxyphenbutazone 134-55-4, Phenyl acetylsalicylate 487-48-9,  
 Salacetamide 515-69-5, .alpha.-Bisabolol 530-78-9, Flufenamic acid  
 552-94-3, Salsalate 644-62-2, Meclofenamic acid 959-10-4, Xenbucin  
 2055-44-9, Perisoxal 2316-64-5, Bromosaligenin 4394-00-7, Niflumic  
 acid 5728-52-9, Felbinac 13710-19-5, Tolfenamic acid 13799-03-6,  
 Protizinic acid 13993-65-2, Metiazinic acid 15307-79-6, Sodium  
 diclofenac 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 17969-20-9,  
 Fenclozic acid 18046-21-4, Fentiazac 18471-20-0, Ditazol  
 20168-99-4,  
 Cinmetacin 20187-55-7, Bendazac 21256-18-8, Oxaprozin 22071-15-4,  
 Ketoprofen 22131-79-9, Alclofenac 22494-42-4, Diflunisal  
 23049-93-6,  
 Enfenamic acid 24237-54-5, Tinoridine 25395-22-6, Salicylamide  
 O-acetic acid 26171-23-3, Tolmetin 27470-51-5, Suxibuzone  
 29679-58-1, Fenoprofen 30544-47-9, Etofenamate 30653-83-9, Parsalmide  
 31793-07-4, Piroprofen 31842-01-0, Indoprofen 32527-55-2, Tiaramide  
 32808-51-8, Bucloxic acid 33005-95-7, Tiaprofenic acid 33369-31-2,  
 Zomepirac 33996-33-7, Oxaceprol 34148-01-1, Clidanac 34552-84-6,  
 Isoxicam 36322-90-4, Piroxicam 36330-85-5, Fenbufen 36981-91-6,  
 Fepradinol 38677-85-9, Flunixin 39718-89-3, Alminoprofen  
 40828-46-4,  
 Suprofen 41340-25-4, Etodolac 42779-82-8, Clopirac 50270-33-2,  
 Isofezolac 51579-82-9, Amfenac 52443-21-7, Glucametacin 52549-17-4,  
 Pranoprofen 53164-05-9, Acemetacin 53597-27-6, Fendosal 53648-05-8,  
 Ibuproxam 53716-49-7, Carprofen 55453-87-7, Isoxepac 55837-18-8,  
 Butibufen 56187-89-4, Ximoprofen 59804-37-4, Tenoxicam 65189-78-8,  
 Tropesin 66934-18-7, Flunoxaprofen 68767-14-6, Loxoprofen  
 70374-39-9, Lornoxicam 71002-09-0, Pirazolac 71125-38-7, Meloxicam  
 74103-06-3, Ketorolac 74711-43-6, Zaltoprofen 76145-76-1, Tomoxiprole  
 78499-27-1, Bermoprofen 78967-07-4, Mofezolac 89796-99-6, Aceclofenac  
 91714-94-2, Bromfenac 99450-52-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (antiinflammatory; synthesis, activity and formulations of  
 pharmaceutical compds. for treatment of oxidative stress and/or

endothelial dysfunction)

IT 58-32-2, Dipyridamole 68-90-6, Benziodarone 100-55-0, Nicotinyl alcohol 322-79-2, Triflusal 390-64-7, Prenylamine 395-28-8, Isoxsuprine 437-74-1, Xanthinol niacinate 447-41-6, Nylidrin 456-59-7, Cycandelate 574-77-6, Papaveroline 987-78-0, Citicoline 3611-72-1, Clobenfuroil 3703-79-5, Bamethan 5638-76-6, Betahistine 6621-47-2, Perhexiline 9005-49-6, Dalteparin, reactions 13042-18-7, Fendiline 14838-15-4, Phenylpropanolamine 22103-14-6, Bufeniode 23210-56-2, Ifenprodil 36702-83-7, Tinofedrine 37270-89-6, Nadroparin calcium 42794-76-3, Midodrine 54767-75-8, Suloctidil 57475-17-9, Brovincamine 57653-27-7, Droprenilamine 63610-08-2, Indobufen 74863-84-6, Argatroban 78919-13-8, Iloprost 81110-73-8, Acetorphan 82571-53-7, Ozagrel 89667-40-3 110140-89-1, Ridogrel 144412-49-7, Lamifiban

RL: RCT (Reactant); RACT (Reactant or reagent)

(antithrombotic; synthesis, activity and formulations of pharmaceutical

compds. for treatment of oxidative stress and/or endothelial dysfunction)

IT 50-44-2, 6-Mercaptopurine 51-21-8, Fluorouracil 53-79-2, Puromycin 54-25-1, 6-Azaauridine 57-22-7, Vincristine 59-05-2, Methotrexate 69-33-0, Tubercidin 84-16-2, Hexestrol 115-02-6, Azaserine

147-94-4,

Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 157-03-9, 6-Diazo-5-oxo-L-norleucine 302-79-4, Retinoic acid 305-03-3, Chlorambucil 320-67-2, Azacitidine 477-30-5, Demecolcine 488-41-5, Mitobronitol 576-68-1, Mannomustine 801-52-5, Porfiromycin

865-21-4,

Vinblastine 1403-28-7, Carzinophilin 1404-15-5, Nogalamycin 1853-37-8, Podophyllic acid 2179-16-0, Ninopterin 2363-58-8, Epitiostanol 3094-09-5, Doxifluridine 3733-81-1, Defosfamide 3930-19-6, Streptonigrin 4803-27-4, Anthramycin 5581-52-2,

Thiamiprine

10318-26-0, Mitolactol 13665-88-8, Mopidamol 18378-89-7, Plicamycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 22006-84-4, Denopterin 22668-01-5, Etanidazole 24280-93-1, Mycophenolic acid 27778-66-1, Tenuazonic acid 29767-20-2, Teniposide 31698-14-3, Ancitabine 33069-62-4, Paclitaxel

33419-42-0,

Etoposide 50264-69-2, Lonidamine 50935-04-1, Carubicin 52128-35-5, Trimetrexate 53643-48-4, Vindesine 53910-25-1, Pentostatin 54083-22-6, Zorubicin 54749-90-5, Chlorozotocin 55726-47-1, Enocitabine 56420-45-2, Epirubicin 58957-92-9, Idarubicin 58970-76-6, Ubenimex 58994-96-0, Ranimustine 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 70052-12-9, Eflornithine 71486-22-1, Vinorelbine 71628-96-1, Menogaril 72496-41-4, Pirarubicin 72732-56-0, Piritrexim 80576-83-6, Edatrexate 82413-20-5, Droloxifene 84088-42-6, Roquinimex 87806-31-3, Porfimer sodium 90357-06-5, Bicalutamide 95058-81-4, Gemcitabine 112887-68-0, Tomudex 114977-28-5, Docetaxel 123948-87-8, Topotecan 126595-07-1, Propagermanium

RL: RCT (Reactant); RACT (Reactant or reagent)

(antitumor; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)

IT 57-08-9, .epsilon.-Acetamidocaproic acid 33159-27-2, Ecabet 34675-84-8, Cetraxate 51481-61-9, Cimetidine 55028-70-1, Araprostil 56695-65-9, Rosaprostol 57381-26-7, Irsogladine 59122-46-2, Misoprostol 64204-55-3, Esaprazole 64218-02-6, Plaunotol

64506-49-6,

Sofalcone 69900-72-7, Trimoprostil 70667-26-4 73121-56-9, Enprostil 73590-58-6, Omeprazole 77287-05-9, Rioprostil 92071-51-7, Rotraxate 102625-70-7, Pantoprazole

RL: RCT (Reactant); RACT (Reactant or reagent)

(antiulcer; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial

- dysfunction)
- IT 50-91-9, Floxuridine 54-42-2, Idoxuridine 70-00-8, Trifluridine 518-28-5, Podophyllotoxin 768-94-5, Amantadine 840-50-6, MADU 1174-11-4, Xenazoic acid 3056-17-5, Stavudine 4097-22-7, Dideoxyadenosine 5536-17-4, Vidarabine 7481-89-2, Zalcitabine 13392-28-4, Rimantadine 15176-29-1, Edoxudine 27762-78-3, Kethoxal 30516-87-1, Zidovudine 36791-04-5, Ribavirin 39809-25-1, Penciclovir 69655-05-6, Didanosine 77181-69-2, Sorivudine 82410-32-0, Ganciclovir 104227-87-4, Famciclovir 113852-37-2, Cidofovir 127779-20-8, Saquinavir 134678-17-4, Lamivudine
- RL: RCT (Reactant); RACT (Reactant or reagent)  
(antiviral; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)
- IT 54-80-8, Pronethalol 2933-94-0, Toliprolol 3930-20-9, Sotalol 5741-22-0, Moprolol 6452-71-7, Oxprenolol 6673-35-4, Practolol 7413-36-7, Nifenalol 13523-86-9 13655-52-2, Alprenolol 14556-46-8, Bupranolol 22664-55-7, Metipranolol 23694-81-7, Mepindolol 26839-75-8, Timolol 29122-68-7, Atenolol 30187-90-7, Xibenolol 34915-68-9, Bunitrolol 34919-98-7, Cetamolol 36894-69-6, Labetalol 37517-30-9, Acebutolol 38363-40-5, Penbutolol 42200-33-9, Nadolol 51384-51-1, Metoprolol 51781-06-7, Carteolol 53684-49-4, Bufetolol 54063-51-3, Nadoxolol 54340-62-4, Bufuralol 56980-93-9, Celiprolol 57460-41-0, Talinolol 57775-29-8, Carazolol 58409-59-9, Bucumolol 58930-32-8, Butofilolol 59170-23-9, Bevantolol 60607-68-3, Indenolol 63659-18-7, Betaxolol 66264-77-5, Sulfinalol 68377-92-4, Arotinolol 72956-09-3, Carvedilol 75659-07-3, Dilevalol 81147-92-4, Esmolol 83688-84-0, Tertatolol 85136-71-6, Tilisolol 85320-68-9, Amosulalol 86880-51-5, Epanolol 118457-14-0, Nebivolol
- RL: RCT (Reactant); RACT (Reactant or reagent)  
(beta-blocker; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)
- IT 2809-21-4, Etidronic acid 15468-10-7, Oxidronic acid 40391-99-9, Pamidronic acid 51395-42-7, Butedronic acid 105462-24-6, Risedronic acid
- RL: RCT (Reactant); RACT (Reactant or reagent)  
(bone resorption inhibitor; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)
- IT 51-43-4, Epinephrine 136-70-9, Protokylol 299-42-3, Ephedrine 497-75-6, Dioxethedrine 519-37-9, Etophylline 530-08-5, Isoetharine 536-24-3, Ethylnorepinephrine 586-06-1, Metaproterenol 603-00-9, Proxiphylline 652-37-9, Acefylline 2016-63-9, Bamifylline
- 3215-70-1, Hexoprenaline 3811-25-4 5205-82-3, Bevonium methyl sulfate 5614-56-2, 1-Theobromineacetic acid 5633-20-5, Oxybutynin 7683-59-2, Isoproterenol 13392-18-2, Fenoterol 13642-52-9, Soterenol 20267-87-2, Diphylline 22254-24-6, Ipratropium bromide 23031-25-6, Terbutaline 30286-75-0, Oxitropium bromide 30392-40-6, Bitolterol 30418-38-3, Tretoquinol 32665-36-4, Eprozinol 32953-89-2, Rimiterol 34866-47-2, Carbuterol 37148-27-9, Clenbuterol 37762-06-4, Zaprinas 38677-81-5, Pirbuterol 41570-61-0, Tulobuterol 48141-64-6, Etafedrine 52109-93-0 54063-54-6, Reproterol 56341-08-3, Mabuterol 63516-07-4, Flutropium bromide 72332-33-3, Procaterol 81732-65-2, Bambuterol 89365-50-4, Salmeterol 129927-33-9, NS-21 136310-93-5, **Tiotropium** bromide 153196-03-3
- RL: RCT (Reactant); RACT (Reactant or reagent)  
(bronchodilator; synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)
- IT 80-53-5, Terpin 90-05-1 93-14-1, Guaifenesin 498-71-5, Sobrerol 1953-02-2, Tiopronin 3572-43-8, Bromhexine 5634-39-9 19767-45-4, Mesna 53943-88-7, Letosteine 61869-07-6, Domiodol 72324-18-6, Stepronin 84611-23-4, Erdosteine

RL: RCT (Reactant); RACT (Reactant or reagent)  
(expectorant; synthesis, activity and formulations of pharmaceutical  
compds. for treatment of oxidative stress and/or endothelial  
dysfunction)

IT 9041-08-1, Reviparin sodium  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(low-mol.-wt. antithrombotic; synthesis, activity and formulations of  
pharmaceutical compds. for treatment of oxidative stress and/or  
endothelial dysfunction)

IT 326850-30-0P 326850-31-1P 326850-32-2P 326850-33-3P 326850-34-4P  
326850-35-5P 326850-36-6P 326850-37-7P 326850-38-8P 326850-39-9P  
326850-40-2P 326850-41-3P 326850-42-4P 326850-43-5P 326850-44-6P  
326850-45-7P 326850-46-8P 326850-47-9P 326850-94-6P  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or  
effector, except adverse); BSU (Biological study, unclassified); SPN  
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);  
PREP (Preparation); USES (Uses)  
(synthesis, activity and formulations of pharmaceutical compds. for  
treatment of oxidative stress and/or endothelial dysfunction)

IT 69-53-4, Ampicillin 103-90-2 105-59-9, N-Methyldiethanolamine  
110-63-4, 1,4-Butanediol, reactions 111-46-6, Diethylene glycol,  
reactions 111-48-8 321-64-2, Tacrine 479-18-5, Diphylline  
525-66-6, Propranolol 591-81-1, 4-Hydroxybutanoic acid 1005-72-7  
1135-24-6, Ferulic acid 1191-25-9, 6-Hydroxyhexanoic acid 3447-95-8  
6007-86-9, Thiophene-2,5-dimethanol 15307-86-5, Diclofenac  
18559-94-9,  
Salbutamol 18683-91-5, Ambroxol 23214-92-8, Doxorubicin 38194-50-2,  
Sulindac 54120-69-3, 1,4-Dioxane-2,6-dimethanol 59277-89-3, Aciclovir  
66376-36-1, Alendronic acid 75847-73-3, Enalapril 79902-63-9,  
Simvastatin 82964-04-3, Tolrestat 83881-51-0, **Cetirizine**  
113665-84-2, Clopidogrel 301669-82-9 326850-58-2 326850-59-3,  
1,4-Dithiane-2,6-dimethanol 326850-60-6, 3-Cyclohexene-1,3-dimethanol  
326850-61-7, 2,5-Thiazoledimethanol 326850-62-8, 2,5-Oxazoledimethanol  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(synthesis, activity and formulations of pharmaceutical compds. for  
treatment of oxidative stress and/or endothelial dysfunction)

IT 41683-29-8P 301669-90-9P 326850-48-0P 326850-49-1P 326850-50-4P  
326850-51-5P 326850-52-6P 326850-53-7P 326850-54-8P 326850-55-9P  
326850-56-0P 326850-57-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(synthesis, activity and formulations of pharmaceutical compds. for  
treatment of oxidative stress and/or endothelial dysfunction)

=> d 7 17 all

L7 NOT FOUND

The L-number entered has not been defined in this session, or it  
has been deleted. To see the L-numbers currently defined in this  
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> l1 and (azelastine or fexofenadine or levocabastine or loratadine or  
mizolastine or ketotifen or emedastine or kimethindene or clemastine or  
bamipine or dexchlorpheniramine or pheniramine or doxylamine or  
chlorphenoxamine or demenhydrinate or diphenhydramine or promethazine or  
ebastine)

L1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 and (azelastine or fexofenadine)

469 AZELASTINE

=&gt; d 1 l1 all

L1 ANSWER 1 OF 93 CAPLUS COPYRIGHT 2003 ACS  
 AN 2003:242164 CAPLUS  
 TI Novel medicaments for inhalation  
 IN Linz, Guenter; Soyka, Rainer  
 PA Boehringer Ingelheim Pharma K.-G., Germany  
 SO PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 IC ICM A61K031-46  
 ICS A61K031-137; A61P011-06; A61P011-08  
 CC 63 (Pharmaceuticals)  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024452	A1	20030327	WO 2002-EP9974	20020906
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10145438	A1	20030403	DE 2001-10145438	20010914
PRAI	DE 2001-10145438	A	20010914		
	DE 2002-10209243	A	20020304		
AB	The invention relates to novel medicament compositions based on <b>tiotropium</b> salts and poorly soluble salmeterol salts. The invention also relates to a method for the production of said compositions and to the use thereof for treating diseases of the respiratory tract.				

=&gt; s 15 and (epinastine or cetirizine)

146 EPINASTINE

622 CETIRIZINE

L8 7 L5 AND (EPINASTINE OR CETIRIZINE)

=&gt; d 2 l2 all

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS  
 AN 1999:449797 CAPLUS  
 DN 131:237677  
 TI Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle  
 AU Cardelu, Ignasi; Anto, Francisca; Beleta, Jorge; Palacios, Jose M.  
 CS Research Center, Pharmacology Department, Almirall Prodesfarma, Barcelona, 08024, Spain  
 SO European Journal of Pharmacology (1999), 374(2), 249-254  
 CODEN: EJPHAZ; ISSN: 0014-2999  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English

CC 1-7 (Pharmacology)

AB Allergic conjunctivitis is the most common ocular allergic disease. Although very symptomatic, it does not endanger vision and topical antihistamines or hormones are the first choice of treatment in clin. practice. Recently, equiv. nanomolar affinities for histamine H1 and muscarinic M1 and M3 cloned human receptors have been reported for desloratadine, the active metabolite of loratadine, a widely prescribed **antihistamine**. This property might enhance its utility in the treatment of asthma, but could induce adverse anticholinergic effects after topical administration. In the present study, we compare the anticholinergic activity of desloratadine with other known muscarinic antagonists and antihistamines on rabbit and guinea-pig iris smooth muscle. Desloratadine was found to be a competitive antagonist ( $pA_2=6.67 \pm 0.09$ ) of carbachol-induced contractions in isolated rabbit iris smooth muscle. Atropine ( $pA_2=9.44 \pm 0.02$ ) and NPC-14695 ( $pA_2=9.18 \pm 0.03$ ) also behaved as competitive antagonists, whereas **tiotropium** bromide ( $pD_2'=9.06 \pm 0.02$ ) exhibited a non-competitive behavior in this tissue. Carebastine ( $pA_2=5.64 \pm 0.04$ ) and fexofenadine ( $pA_2 < 4.0$ ) were also studied. After topical administration on the guinea-pig eye conjunctiva, desloratadine produced a potent ( $ED_{50}=2.3$  mg/mL) and long lasting mydriasis ( $>120$  min at the  $ED_{50}$ ) in conscious animals. Fexofenadine and carebastine were inactive even at the highest concn. tested (10 mg/mL). Atropine ( $ED_{50}=30$   $\mu$ g/mL) and **tiotropium** bromide ( $ED_{50}=10$   $\mu$ g/mL) were much more potent than desloratadine or pirenzepine ( $ED_{50}=3$  mg/mL) in this model. The competitive muscarinic antagonism of desloratadine in vitro, and its potency and duration of action in vivo, suggest that topical treatment of allergic conjunctivitis and rhinitis with desloratadine could produce undesirable peripheral anticholinergic side effects such as mydriasis and xerostomia.

ST desloratadine anticholinergic iris mydriasis conjunctivitis rhinitis

IT Eye, disease  
(allergic conjunctivitis; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Allergy inhibitors  
Antihistamines  
Cholinergic antagonists  
Muscarinic antagonists  
(anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

iris smooth muscle)

IT Eye  
(iris dilator muscle; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Eye, disease  
(mydriasis; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Mouth  
(xerostomia; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT 100643-71-8, Desloratadine  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Arunlakshana, A; Br J Pharmacol 1959, V14, P48
- (2) Bogнар, I; Eur J Pharmacol 1989, V163, P263 CAPLUS
- (3) Bogнар, I; Naunyn-Schmiedeberg's Arch Pharmacol 1990, V341, P22 CAPLUS
- (4) Bogнар, I; Naunyn-Schmiedeberg's Arch Pharmacol 1992, V345, P611 CAPLUS
- (5) Cardelus, I; Br J Pharmacol 1998, V123, P267P
- (6) Choppin, A; Br J Pharmacol 1998, V124, P883 CAPLUS
- (7) Clissold, S; Drugs 1989, V37, P42 CAPLUS

- (8) Davies, R; Clin Exp Allergy 1996, V26, P11
- (9) Disse, B; Life Sciences 1993, V52, P537 CAPLUS
- (10) Disse, B; Life Sciences 1999, V64, P457 CAPLUS
- (11) Eglen, R; Pharmacol Rev 1996, V48, P531 CAPLUS
- (12) Fuder, H; J Ocul Pharmacol 1994, V10, P109 CAPLUS
- (13) Genovese, A; Clin Exp Allergy 1997, V27, P559 CAPLUS
- (14) Gil, D; Invest Ophthalmol Visual Sci 1997, V38, P1434 MEDLINE
- (15) Handley, D; Ann Allergy Asthma Immunol 1997, V78, PP164
- (16) Handley, D; Expert Opinion on Investigational Drugs 1998, V7, P1045 CAPLUS
- (17) Haria, M; Drugs 1994, V48, P617 MEDLINE
- (18) Hingorani, M; Expert Opinion on Investigational Drugs 1998, V7, P27 CAPLUS
- (19) Howell, R; J Pharmacol Exp Ther 1994, V270, P546 CAPLUS
- (20) Ishizaka, N; Brain Res 1998, V787, P344 CAPLUS
- (21) Kaiser, C; J Med Chem 1993, V36, P610 CAPLUS
- (22) Maesen, F; Eur Respir J 1995, V8, P1506 CAPLUS
- (23) Norohna-Blob, L; J Pharmacol Exp Ther 1991, V5, P562
- (24) Tallarida, R; The Dose-Response Relation in Pharmacology 1979
- (25) Vignola, A; Allergy 1995, V50, P200 CAPLUS
- (26) Weyer, A; J Allergy Clin Immunol 1992, V89, P222
- (27) Woldemussie, E; Exp Eye Res 1993, V56, P385 CAPLUS
- (28) Yoshitomi, T; Graefe's Arch Clin Exp Ophthalmol 1995, V233, P181 CAPLUS
- (29) Yumibe, N; Biochem Pharmacol 1996, V51, P165 CAPLUS

=> d 3 13 all

L3 ANSWER 3 OF 624 CAPLUS COPYRIGHT 2003 ACS  
 AN 2003:203393 CAPLUS  
 DN 138:226774  
 TI Preparation of liquid and semisolid dosage forms containing drug tannate salts  
 IN Kiel, Jeffrey S.; Thomas, H. Greg; Mani, Narasimhan  
 PA USA  
 SO U.S. Pat. Appl. Publ., 8 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-7024  
 ICS C07H013-02  
 NCL 514023000; 536110000  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003050252	A1	20030313	US 2002-119285	20020409
PRAI	US 2001-282969P	P	20010410		

AB An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purifn. is then added to a liq. or semi-solid medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liq. or semi-solid medium to generate a therapeutic dosage form. A suspension with xanthan gum as thickening agent was prepd. from a formulation contg. pseudoephedrine tannate 1.500, diphenhydramine tannate 0.500, saccharin sodium 0.300, sucrose 10.000, glycerin 7.500, Mg Al silicate 0.800, xanthan gum 0.520, dibasic sodium phosphate 1.000, methylparaben 0.200, sodium benzoate 0.100, FD&C Red No.-40 0.040, strawberry flavor 0.500, and water qs to 100%.



ST drug tannate salt liq dosage form; semisolid dosage form drug tannate salt

IT Drug delivery systems  
(liqs.; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Antihistamines  
Antitussives  
Cholinergic antagonists  
Decongestants  
Flavoring materials  
Preservatives  
Sweetening agents  
Thickening agents  
(prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Paraffin oils  
Tannins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Drug delivery systems  
(semisolid; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Drug delivery systems  
(suspensions; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Kaolin, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(thickener; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT 56-81-5, Glycerin, biological studies 57-27-2, Morphine, biological studies 57-55-6, Propylene glycol, biological studies 58-73-1, Diphenhydramine 58-73-1D, Diphenhydramine, tannic acid salts 59-33-6, Pyrilamine maleate 59-42-7, Phenylephrine 59-42-7D, Phenylephrine, tannic acid salts 60-87-7, Promethazine 61-76-7, Phenylephrine hydrochloride 64-17-5, Ethanol, biological studies 67-63-0, Isopropyl alcohol, biological studies 68-88-2, Hydroxyzine 76-42-6, Oxycodone 76-57-3, Codeine 77-23-6, Carbetapentane 82-88-2, Phenindamine 82-93-9, Chlorcyclizine 84-96-8, Trimeprazine 86-21-5, Pheniramine 86-22-6, Brompheniramine 90-82-4, Pseudoephedrine 90-82-4D, Pseudoephedrine, tannic acid salts 91-81-6, Tripeleminamine 91-84-9, Pyrilamine 91-84-9D, Pyrilamine, tannic acid salts 92-12-6, Phenyltoloxamine 118-23-0, Bromodiphenhydramine 125-29-1, Hydrocodone 125-69-9, Dextromethorphan hydrobromide 125-71-3, Dextromethorphan 129-03-3, Cyproheptadine 132-22-9, Chlorpheniramine 132-22-9D, Chlorpheniramine, tannic acid salts 299-42-3, Ephedrine 345-78-8, Pseudoephedrine hydrochloride 469-21-6, Doxylamine 486-12-4, Triprolidine 486-16-8, Carbinoxamine 523-87-5, Dimenhydrinate 569-65-3, Meclizine 13265-10-6, Methscopolamine 15686-51-8,

Clemastine  
23142-01-0, Carbetapentane citrate 79794-75-5, Loratadine 83799-24-0, Fexofenadine 83881-51-0, **Cetirizine** 87848-99-5, Acrivastine 100643-71-8, Desloratadine  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT 1327-43-1, Magnesium aluminum silicate 9000-69-5, Pectin 9004-34-6, Cellulose, biological studies 9004-65-3, HPMC 11138-66-2, Xanthan gum  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(thickener; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

=> d 4 l4 all

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:353315 CAPLUS  
DN 136:374833

TI Inhalant composition containing **tiotropium** salts and  
anti-histamines  
IN Pairet, Michel; Pieper, Michael Paul; Meade, Christopher John Montague;  
Schmelzer, Christel  
PA Boehringer Ingelheim Pharma Kg, Germany  
SO PCT Int. Appl., 29 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
IC ICM A61K045-00  
CC 63-6 (Pharmaceuticals)  
Section cross-reference(s): 1  
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002036163	A2	20020510	WO 2001-EP12510	20011023
	WO 2002036163	A3	20021212		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10138272	A1	20030227	DE 2001-10138272	20010810
	US 2002151541	A1	20021017	US 2001-7182	20011019
	US 2002183292	A1	20021205	US 2001-86145	20011019
	AU 2002014030	A5	20020515	AU 2002-14030	20011023
	US 2002137764	A1	20020926	US 2001-40196	20011025
PRAI	DE 2000-10054042	A	20001031		
	DE 2001-10138272	A	20010810		
	US 2000-253613P	P	20001128		
	DE 2000-10062712	A	20001215		
	US 2000-257220P	P	20001221		
	US 2001-314599P	P	20010824		
	WO 2001-EP12510	W	20011023		
AB	The invention relates to inhalant compns. based on <b>tiotropium</b> salts and anti-histamines, a method for their prodn. and their use for treating respiratory illnesses, e.g. allergic and non-allergic rhinitis. Thus and inhalation powder contained per microcapsule (.mu.g): <b>tiotropium</b> bromide 21.7; <b>epinastine</b> -hydrochloride 200; lactose 4778.3.				
ST	<b>tiotropium</b> antihistamine inhalant nose allergy				
IT	Quaternary ammonium compounds, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkylbenzylidimethyl, chlorides; inhalant compn. contg. <b>tiotropium</b> salts and anti-histamines)				
IT	Respiratory tract (allergy; inhalant compn. contg. <b>tiotropium</b> salts and anti-histamines)				
IT	Respiratory tract (disease; inhalant compn. contg. <b>tiotropium</b> salts and anti-histamines)				
IT	Glycols, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ethers; inhalant compn. contg. <b>tiotropium</b> salts and anti-histamines)				
IT	Ethers, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (glycol; inhalant compn. contg. <b>tiotropium</b> salts and anti-histamines)				
IT	Hydrocarbons, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (halo; inhalant compn. contg. <b>tiotropium</b> salts and				

anti-histamines)

IT Antihistamines  
Antioxidants  
Complexing agents  
Lubricants  
Particle size  
Propellants (sprays and foams)  
Stabilizing agents  
Surfactants  
pH  
(inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Monosaccharides  
Oligosaccharides, biological studies  
Polyoxyalkylenes, biological studies  
Polysaccharides, biological studies  
Tocopherols  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Drug delivery systems  
(inhalants; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Medical goods  
(inhalers; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Drug delivery systems  
(microcapsules; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Alcohols, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyhydric; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT Drug delivery systems  
(suspensions; inhalant compn. contg. **tiotropium** salts and anti-histamines)

IT 50-81-7, L-Ascorbic acid, biological studies 56-81-5, Glycerol, biological studies 57-55-6, Propylene glycol, biological studies 58-73-1, Diphenhydramine 60-00-4, EDTA, biological studies 60-87-7, Promethazine 64-17-5, Ethanol, biological studies 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 65-85-0, Benzoic acid, biological studies 65-85-0D, Benzoic acid, salts 74-82-8D, Methane, halogenated derivs. 74-84-0D, Ethane, halogenated derivs. 74-98-6, Propane, biological studies 74-98-6D, Propane, halogenated derivs. 75-19-4D, Cyclopropane, halogenated derivs. 75-28-5, Isobutane 77-38-3, Chlorphenoxamine 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 86-21-5, Pheniramine 106-97-8, Butane, biological studies 106-97-8D, Butane, halogenated derivs. 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 123-03-5, Cetylpyridinium chloride 139-33-3 287-23-0D, Cyclobutane, halogenated derivs. 431-89-0, TG 227 469-21-6,  
Doxylamine 523-87-5, Dimenhydrinate 526-83-0, Tartaric acid 569-65-3, Meclozine 811-97-2, TG 134a 1406-18-4, Vitamin E 4945-47-5, Bamipine 5636-83-9, Dimetindene 6915-15-7, Malic acid 7647-01-0, Hydrochloric acid, biological studies 7664-93-9, Sulfuric acid, biological studies 7697-37-2, Nitric acid, biological studies 10035-10-6, Hydrobromic acid, biological studies 11103-57-4, Vitamin A 15686-51-8, Clemastine 25322-68-3, Polyethylene glycol 25322-69-4, Polypropylene glycol 34580-13-7, Ketotifen 58581-89-8, Azelastine 79516-68-0, Levocabastine 79794-75-5, Loratadine 80012-43-7, **Epinastine** 83799-24-0, Fexofenadine 83881-51-0, **Cetirizine** 87233-61-2, Emedastine 90729-43-4, Ebastine 100643-71-8, Desloratadine 108612-45-9, Mizolastine 108929-04-0, **Epinastine** hydrochloride 136310-93-5, **Tiotropium** bromide 186691-13-4D, **Tiotropium**, salts 412010-60-7 412010-61-8 412010-62-9 412010-63-0 412010-64-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(inhalant compn. contg. **tiotropium** salts and anti-histamines)

=> s l1 and (azelastine or fexofenadine)

469 AZELASTINE

264 FEXOFENADINE

L9 6 L1 AND (AZELASTINE OR FEXOFENADINE)

=> d 1 l1 all

L1 ANSWER 1 OF 93 CAPLUS COPYRIGHT 2003 ACS

AN 2003:242164 CAPLUS

TI Novel medicaments for inhalation

IN Linz, Guenter; Soyka, Rainer

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM A61K031-46

ICS A61K031-137; A61P011-06; A61P011-08

CC 63 (Pharmaceuticals)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024452	A1	20030327	WO 2002-EP9974	20020906
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

DE 10145438 A1 20030403 DE 2001-10145438 20010914

PRAI DE 2001-10145438 A 20010914

DE 2002-10209243 A 20020304

AB The invention relates to novel medicament compositions based on **tiotropium** salts and poorly soluble salmeterol salts. The invention also relates to a method for the production of said compositions and to the use thereof for treating diseases of the respiratory tract.

=> d 2 l2 all

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

AN 1999:449797 CAPLUS

DN 131:237677

TI Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle

AU Cardelu, Ignasi; Anto, Francisca; Beleta, Jorge; Palacios, Jose M.

CS Research Center, Pharmacology Department, Almirall Prodesfarma, Barcelona,

08024, Spain

SO European Journal of Pharmacology (1999), 374(2), 249-254

CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier Science B.V.

DT Journal

LA English  
CC 1-7 (Pharmacology)  
AB Allergic conjunctivitis is the most common ocular allergic disease. Although very symptomatic, it does not endanger vision and topical antihistamines or hormones are the first choice of treatment in clin. practice. Recently, equiv. nanomolar affinities for histamine H1 and muscarinic M1 and M3 cloned human receptors have been reported for desloratadine, the active metabolite of loratadine, a widely prescribed **antihistamine**. This property might enhance its utility in the treatment of asthma, but could induce adverse anticholinergic effects after topical administration. In the present study, we compare the anticholinergic activity of desloratadine with other known muscarinic antagonists and antihistamines on rabbit and guinea-pig iris smooth muscle. Desloratadine was found to be a competitive antagonist ( $pA_2=6.67 \pm 0.09$ ) of carbachol-induced contractions in isolated rabbit iris smooth muscle. Atropine ( $pA_2=9.44 \pm 0.02$ ) and NPC-14695 ( $pA_2=9.18 \pm 0.03$ ) also behaved as competitive antagonists, whereas **tiotropium** bromide ( $pD_2'=9.06 \pm 0.02$ ) exhibited a non-competitive behavior in this tissue. Carebastine ( $pA_2=5.64 \pm 0.04$ ) and fexofenadine ( $pA_2<4.0$ ) were also studied. After topical administration on the guinea-pig eye conjunctiva, desloratadine produced a potent ( $ED_{50}=2.3$  mg/mL) and long lasting mydriasis ( $>120$  min at the  $ED_{50}$ ) in conscious animals. Fexofenadine and carebastine were inactive even at the highest concn. tested (10 mg/mL). Atropine ( $ED_{50}=30$  .mu.g/mL) and **tiotropium** bromide ( $ED_{50}=10$  .mu.g/mL) were much more potent than desloratadine or pirenzepine ( $ED_{50}=3$  mg/mL) in this model. The competitive muscarinic antagonism of desloratadine in vitro, and its potency and duration of action in vivo, suggest that topical treatment of allergic conjunctivitis and rhinitis with desloratadine could produce undesirable peripheral anticholinergic side effects such as mydriasis and xerostomia.

ST desloratadine anticholinergic iris mydriasis conjunctivitis rhinitis  
IT Eye, disease  
(allergic conjunctivitis; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Allergy inhibitors  
Antihistamines  
Cholinergic antagonists  
Muscarinic antagonists  
(anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

iris smooth muscle)

IT Eye  
(iris dilator muscle; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Eye, disease  
(mydriasis; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT Mouth  
(xerostomia; anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

IT 100643-71-8, Desloratadine  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(anticholinergic effects of loratadine metabolite desloratadine in iris smooth muscle)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

(1) Arunlakshana, A; Br J Pharmacol 1959, V14, P48  
(2) Bognar, I; Eur J Pharmacol 1989, V163, P263 CAPLUS  
(3) Bognar, I; Naunyn-Schmiedeberg's Arch Pharmacol 1990, V341, P22 CAPLUS  
(4) Bognar, I; Naunyn-Schmiedeberg's Arch Pharmacol 1992, V345, P611 CAPLUS  
(5) Cardelus, I; Br J Pharmacol 1998, V123, P267P  
(6) Choppin, A; Br J Pharmacol 1998, V124, P883 CAPLUS

- (7) Clissold, S; Drugs 1989, V37, P42 CAPLUS
- (8) Davies, R; Clin Exp Allergy 1996, V26, P11
- (9) Disse, B; Life Sciences 1993, V52, P537 CAPLUS
- (10) Disse, B; Life Sciences 1999, V64, P457 CAPLUS
- (11) Eglen, R; Pharmacol Rev 1996, V48, P531 CAPLUS
- (12) Fuder, H; J Ocul Pharmacol 1994, V10, P109 CAPLUS
- (13) Genovese, A; Clin Exp Allergy 1997, V27, P559 CAPLUS
- (14) Gil, D; Invest Ophthalmol Visual Sci 1997, V38, P1434 MEDLINE
- (15) Handley, D; Ann Allergy Asthma Immunol 1997, V78, PP164
- (16) Handley, D; Expert Opinion on Investigational Drugs 1998, V7, P1045 CAPLUS
- (17) Haria, M; Drugs 1994, V48, P617 MEDLINE
- (18) Hingorani, M; Expert Opinion on Investigational Drugs 1998, V7, P27 CAPLUS
- (19) Howell, R; J Pharmacol Exp Ther 1994, V270, P546 CAPLUS
- (20) Ishizaka, N; Brain Res 1998, V787, P344 CAPLUS
- (21) Kaiser, C; J Med Chem 1993, V36, P610 CAPLUS
- (22) Maesen, F; Eur Respir J 1995, V8, P1506 CAPLUS
- (23) Norohna-Blob, L; J Pharmacol Exp Ther 1991, V5, P562
- (24) Tallarida, R; The Dose-Response Relation in Pharmacology 1979
- (25) Vignola, A; Allergy 1995, V50, P200 CAPLUS
- (26) Weyer, A; J Allergy Clin Immunol 1992, V89, P222
- (27) Woldemussie, E; Exp Eye Res 1993, V56, P385 CAPLUS
- (28) Yoshitomi, T; Graefe's Arch Clin Exp Ophthalmol 1995, V233, P181 CAPLUS
- (29) Yumibe, N; Biochem Pharmacol 1996, V51, P165 CAPLUS

=> d 3 13 all

L3 ANSWER 3 OF 624 CAPLUS COPYRIGHT 2003 ACS  
 AN 2003:203393 CAPLUS  
 DN 138:226774  
 TI Preparation of liquid and semisolid dosage forms containing drug tannate salts  
 IN Kiel, Jeffrey S.; Thomas, H. Greg; Mani, Narasimhan  
 PA USA  
 SO U.S. Pat. Appl. Publ., 8 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-7024  
 ICS C07H013-02  
 NCL 514023000; 536110000  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003050252	A1	20030313	US 2002-119285	20020409
PRAI	US 2001-282969P	P	20010410		

AB An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purifn. is then added to a liq. or semi-solid

medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liq. or semi-solid medium to generate a therapeutic dosage form. A suspension with xanthan gum as thickening agent was prepd. from a formulation contg. pseudoephedrine tannate 1.500, diphenhydramine tannate 0.500, saccharin sodium 0.300, sucrose 10.000, glycerin 7.500, Mg Al silicate 0.800, xanthan gum 0.520, dibasic sodium phosphate 1.000, methylparaben 0.200, sodium benzoate 0.100, FD&C Red No.-40 0.040, strawberry flavor 0.500, and

water qs to 100%.

ST drug tannate salt liq dosage form; semisolid dosage form drug tannate salt

IT Drug delivery systems  
(liqs.; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Antihistamines  
Antitussives  
Cholinergic antagonists  
Decongestants  
Flavoring materials  
Preservatives  
Sweetening agents  
Thickening agents  
(prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Paraffin oils  
Tannins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Drug delivery systems  
(semisolid; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Drug delivery systems  
(suspensions; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT Kaolin, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(thickener; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT 56-81-5, Glycerin, biological studies 57-27-2, Morphine, biological studies 57-55-6, Propylene glycol, biological studies 58-73-1, Diphenhydramine 58-73-1D, Diphenhydramine, tannic acid salts 59-33-6, Pyrilamine maleate 59-42-7, Phenylephrine 59-42-7D, Phenylephrine, tannic acid salts 60-87-7, Promethazine 61-76-7, Phenylephrine hydrochloride 64-17-5, Ethanol, biological studies 67-63-0, Isopropyl alcohol, biological studies 68-88-2, Hydroxyzine 76-42-6, Oxycodone 76-57-3, Codeine 77-23-6, Carbetapentane 82-88-2, Phenindamine 82-93-9, Chlorcyclizine 84-96-8, Trimeprazine 86-21-5, Pheniramine 86-22-6, Brompheniramine 90-82-4, Pseudoephedrine 90-82-4D, Pseudoephedrine, tannic acid salts 91-81-6, Tripeleminamine 91-84-9, Pyrilamine 91-84-9D, Pyrilamine, tannic acid salts 92-12-6, Phenyltoloxamine 118-23-0, Bromodiphenhydramine 125-29-1, Hydrocodone 125-69-9, Dextromethorphan hydrobromide 125-71-3, Dextromethorphan 129-03-3, Cyproheptadine 132-22-9, Chlorpheniramine 132-22-9D, Chlorpheniramine, tannic acid salts 299-42-3, Ephedrine 345-78-8, Pseudoephedrine hydrochloride 469-21-6, Doxylamine 486-12-4, Triprolidine 486-16-8, Carbinoxamine 523-87-5, Dimenhydrinate 569-65-3, Meclizine 13265-10-6, Methscopolamine 15686-51-8,

Clemastine  
23142-01-0, Carbetapentane citrate 79794-75-5, Loratadine 83799-24-0, Fexofenadine 83881-51-0, **Cetirizine** 87848-99-5, Acrivastine 100643-71-8, Desloratadine  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

IT 1327-43-1, Magnesium aluminum silicate 9000-69-5, Pectin 9004-34-6, Cellulose, biological studies 9004-65-3, HPMC 11138-66-2, Xanthan gum  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(thickener; prepn. of liq. and semisolid dosage forms contg. drug tannate salts)

=> s l1 and (loratadine or mizolastine or emedastine)\_

MISSING OPERATOR MEDASTINE)\_

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 and (loratadine or mizolastine or emedastine)

503 LORATADINE  
127 MIZOLASTINE  
81 EMEDASTINE

L10 4 L1 AND (LORATADINE OR MIZOLASTINE OR EMEDASTINE)

=> d 1 l1 all

L1 ANSWER 1 OF 93 CAPLUS COPYRIGHT 2003 ACS  
AN 2003:242164 CAPLUS  
TI Novel medicaments for inhalation  
IN Linz, Guenter; Soyka, Rainer  
PA Boehringer Ingelheim Pharma K.-G., Germany  
SO PCT Int. Appl., 29 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
IC ICM A61K031-46  
ICS A61K031-137; A61P011-06; A61P011-08  
CC 63 (Pharmaceuticals)  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024452	A1	20030327	WO 2002-EP9974	20020906
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10145438	A1	20030403	DE 2001-10145438	20010914
PRAI	DE 2001-10145438	A	20010914		
	DE 2002-10209243	A	20020304		
AB	The invention relates to novel medicament compositions based on <b>tiotropium</b> salts and poorly soluble salmeterol salts. The invention also relates to a method for the production of said compositions and to the use thereof for treating diseases of the respiratory tract.				